Evidence map›Paper›PMID 38473261›Full record

ArticleCancers2024

Targeted DNA Methylation Editing Using an All-in-One System Establishes Paradoxical Activation of

Rakesh Banerjee, Priyadarshana Ajithkumar, Nicholas Keestra, Jim Smith, Gregory Gimenez, Euan J Rodger, Michael R Eccles, Jisha Antony, Robert J Weeks, Aniruddha Chatterjee

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Rakesh BanerjeeDepartment of Pathology, Dunedin School of Medicine, University of Otago, Dunedin 9054, New Zealand.ORCID 0000-0002-9768-1679
Priyadarshana AjithkumarDepartment of Pathology, Dunedin School of Medicine, University of Otago, Dunedin 9054, New Zealand.
Nicholas KeestraDepartment of Pathology, Dunedin School of Medicine, University of Otago, Dunedin 9054, New Zealand.
Jim SmithDepartment of Pathology, Dunedin School of Medicine, University of Otago, Dunedin 9054, New Zealand.
Gregory GimenezDepartment of Pathology, Dunedin School of Medicine, University of Otago, Dunedin 9054, New Zealand.
Euan J RodgerDepartment of Pathology, Dunedin School of Medicine, University of Otago, Dunedin 9054, New Zealand.ORCID 0000-0002-9615-5896
Michael R EcclesDepartment of Pathology, Dunedin School of Medicine, University of Otago, Dunedin 9054, New Zealand.ORCID 0000-0002-6824-8761
Jisha AntonyDepartment of Pathology, Dunedin School of Medicine, University of Otago, Dunedin 9054, New Zealand.
Robert J WeeksDepartment of Pathology, Dunedin School of Medicine, University of Otago, Dunedin 9054, New Zealand.
Aniruddha ChatterjeeDepartment of Pathology, Dunedin School of Medicine, University of Otago, Dunedin 9054, New Zealand.ORCID 0000-0001-7276-2248
University of Otago · NZUniversity of Petroleum and Energy Studies · IN

Funding

Marsden Start Fund (RSNZ), Rutherford Discovery Fellowship to Aniruddha Chatterjee, Maurice Phyllis Paykel Trust Funding and Internal funds from University of Otago 17-UOO-240, RDF17-06
6 · The paper itself

Abstract

Cutaneous melanoma is rapidly on the rise globally, surpassing the growth rate of other cancers, with metastasis being the primary cause of death in melanoma patients. Consequently, understanding the mechanisms behind this metastatic process and exploring innovative treatments is of paramount importance. Recent research has shown promise in unravelling the role of epigenetic factors in melanoma progression to metastasis. While DNA hypermethylation at gene promoters typically suppresses gene expression, we have contributed to establishing the newly understood mechanism of paradoxical activation of genes via DNA methylation, where high methylation coincides with increased gene activity. This mechanism challenges the conventional paradigm that promoter methylation solely silences genes, suggesting that, for specific genes, it might actually activate them. Traditionally, altering DNA methylation in vitro has involved using global demethylating agents, which is insufficient for studying the mechanism and testing the direct consequence of gene methylation changes. To investigate promoter hypermethylation and its association with gene activation, we employed a novel approach utilising a CRISPR-SunTag All-in-one system. Here, we focused on editing the DNA methylation of a specific gene promoter segment (

Indexed as

All-in-one CRISPR systemDNA methylationepigenomic editingmelanomaparadoxical roleRNA-sequencing

Identifiers

PMID38473261
PMCPMC10930647
OpenAlexW4392101482

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.